Sign In
Buy NOVN
$0.0941
+0 (+0%)
At Close: Nov 20, 2023
Novan, Inc. (NOVN) Q3 2022 Earnings Call Transcript
02:40am, Tuesday, 15'th Nov 2022
Novan, Inc. (NASDAQ:NOVN ) Q3 2022 Earnings Conference Call November 14, 2022 8:30 AM ET Company Participants Paula Brown Stafford - Chairman, President, and Chief Executive Officer John Gay - Chief F
New long-term Leqvio® (inclisiran) data from Novartis show sustained efficacy and safety over four years
09:24pm, Monday, 07'th Nov 2022 GlobeNewswire Inc.
Basel, November 7, 2022 — Novartis today announced results from the Phase II open-label extension ORION-3 trial, which showed that Leqvio provides effective low-density lipoprotein cholesterol (LDL-
Novan to Report Third Quarter 2022 Financial Results on November 14, 2022
02:00pm, Monday, 07'th Nov 2022 GlobeNewswire Inc.
DURHAM, N.C., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its third quarter 2022 financial results on Monday,
Sandoz announces further investment in key manufacturing facility in Austria, to support increased global demand for essential antibiotics
11:00am, Monday, 07'th Nov 2022 GlobeNewswire Inc.
Basel, November 7, 2022 – Sandoz, a global leader in generic and biosimilar medicines, today announced an additional investment of EUR 50 million to support increased European manufacturing capacity
Is Vanguard International Dividend Appreciation ETF (VIGI) a Strong ETF Right Now?
10:20am, Thursday, 27'th Oct 2022 Zacks Investment Research
Smart Beta ETF report for VIGI
Novartis maintains growth momentum and confirms FY’22 Group guidance
05:00am, Tuesday, 25'th Oct 2022 GlobeNewswire Inc.
Ad hoc announcement pursuant to Art. 53 LR
Novartis setzt die Wachstumsdynamik fort und bestätigt die Konzernprognose für das Geschäftsjahr 2022
05:00am, Tuesday, 25'th Oct 2022 GlobeNewswire Inc.
Ad-hoc-Mitteilung gemäss Art. 53 KR
Is WisdomTree International High Dividend ETF (DTH) a Strong ETF Right Now?
10:20am, Monday, 24'th Oct 2022 Zacks Investment Research
Smart Beta ETF report for DTH
Novartis hemoglobinuria trial meets two primary endpoints
06:27am, Monday, 24'th Oct 2022 MarketWatch
The trial studied a drug named Iptacopan and established its superiority to a previously used treatment in helping patients with debilitating anemia.
Novartis investigational oral monotherapy iptacopan demonstrates clinically meaningful superiority over anti-C5 treatment in Phase III APPLY-PNH study
05:15am, Monday, 24'th Oct 2022 GlobeNewswire Inc.
Ad hoc announcement pursuant to Art. 53 LR
EPI Health, a Novan Company, and MC2 Therapeutics Present New Data In Multiple Posters Highlighting WYNZORA’s® Unique PAD Technology™ at the 42nd Annual Fall Clinical Dermatology Conference®
12:35pm, Friday, 21'st Oct 2022 GlobeNewswire Inc.
Research shows PAD (Polyaphron Dispersion) Technology™ leads to more efficient delivery of Calcipotriene (CAL) and Betamethasone Dipropionate (BDP) than CAL/BDP topical suspension Research shows PA
EPI Health, a Novan Company, and MC2 Therapeutics Announce Data from Survey Conducted by National Psoriasis Foundation Presented at 42nd Annual Fall Clinical Dermatology Conference®
12:35pm, Friday, 21'st Oct 2022 GlobeNewswire Inc.
Data collected shows importance of treatment formulation characteristics and speed of improvement in psoriasis symptoms to patient treatment adherence Data collected shows importance of treatment form
Novan and EPI Health, a Novan Company, Announce Abstracts Accepted for Poster Presentation at the 42nd Annual Fall Clinical Dermatology Conference®
12:30pm, Friday, 14'th Oct 2022 GlobeNewswire Inc.
DURHAM, N.C., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN) and EPI Health, a Novan Company, today announced that eight abstracts have been accepted
Novartis receives positive CHMP opinion for Pluvicto® for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer
11:04am, Friday, 14'th Oct 2022 GlobeNewswire Inc.
Basel, October 14, 2022 — Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommende
Why Immunic Shares Jumped By Around 57%; Here Are 73 Biggest Movers From Yesterday
06:17am, Tuesday, 11'th Oct 2022 Benzinga
Gainers
Applied DNA Sciences, Inc. (NASDAQ: APDN) shares climbed 71% to close at $2.12 on Monday after the company announced it has received its largest single purchase order for LinearDNA™ valued
